1. Home
  2. PRTA vs CCO Comparison

PRTA vs CCO Comparison

Compare PRTA & CCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTA
  • CCO
  • Stock Information
  • Founded
  • PRTA 2012
  • CCO 1995
  • Country
  • PRTA Ireland
  • CCO United States
  • Employees
  • PRTA N/A
  • CCO N/A
  • Industry
  • PRTA Biotechnology: Pharmaceutical Preparations
  • CCO Advertising
  • Sector
  • PRTA Health Care
  • CCO Consumer Discretionary
  • Exchange
  • PRTA Nasdaq
  • CCO Nasdaq
  • Market Cap
  • PRTA 809.8M
  • CCO 472.0M
  • IPO Year
  • PRTA N/A
  • CCO 2005
  • Fundamental
  • Price
  • PRTA $9.20
  • CCO $0.96
  • Analyst Decision
  • PRTA Buy
  • CCO Buy
  • Analyst Count
  • PRTA 9
  • CCO 3
  • Target Price
  • PRTA $54.57
  • CCO $2.05
  • AVG Volume (30 Days)
  • PRTA 572.3K
  • CCO 2.7M
  • Earning Date
  • PRTA 05-07-2025
  • CCO 05-01-2025
  • Dividend Yield
  • PRTA N/A
  • CCO N/A
  • EPS Growth
  • PRTA N/A
  • CCO N/A
  • EPS
  • PRTA N/A
  • CCO N/A
  • Revenue
  • PRTA $135,157,000.00
  • CCO $1,505,230,000.00
  • Revenue This Year
  • PRTA N/A
  • CCO $6.83
  • Revenue Next Year
  • PRTA $131.71
  • CCO $3.73
  • P/E Ratio
  • PRTA N/A
  • CCO N/A
  • Revenue Growth
  • PRTA 47.92
  • CCO 4.95
  • 52 Week Low
  • PRTA $9.10
  • CCO $0.81
  • 52 Week High
  • PRTA $25.42
  • CCO $1.88
  • Technical
  • Relative Strength Index (RSI)
  • PRTA 26.58
  • CCO 39.42
  • Support Level
  • PRTA $9.30
  • CCO $0.89
  • Resistance Level
  • PRTA $10.45
  • CCO $1.04
  • Average True Range (ATR)
  • PRTA 0.81
  • CCO 0.10
  • MACD
  • PRTA -0.15
  • CCO 0.00
  • Stochastic Oscillator
  • PRTA 2.77
  • CCO 44.12

About PRTA Prothena Corporation plc

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

Share on Social Networks: